Lead Product(s) : Mim8
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Details : NNC0365-3769 (Mim8) is a next-generation FVIIIa mimetic antibody delivering haemostasis for once-weekly or once-monthly prophylaxis for people living with haemophilia A, with and without inhibitors.
Product Name : NNC0365-3769
Product Type : Antibody
Upfront Cash : Inapplicable
February 07, 2025
Lead Product(s) : Mim8
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dasiglucagon
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Declines to Approve Zealand's Drug for Low Blood Sugar in Infants
Details : ZP4207 (dasiglucagon) is a glucagon receptor agonist, peptide drug candidate, which is currently being evaluated for the treatment of congenital hyperinsulinism.
Product Name : Zegalogue
Product Type : Hormone
Upfront Cash : Inapplicable
August 10, 2024
Lead Product(s) : Dasiglucagon
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mim8
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mim8 Show Superior Reduction in Bleeding Rate Compared to Prior Treatment in Haemophilia A
Details : NNC0365-3769 (Mim8) is a next-generation FVIIIa mimetic antibody delivering haemostasis for once-weekly or once-monthly prophylaxis for people living with haemophilia A, with and without inhibitors.
Product Name : NNC0365-3769
Product Type : Antibody
Upfront Cash : Inapplicable
June 23, 2024
Lead Product(s) : Mim8
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mim8
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novo Nordisk A/S: Mim8 Shows Superior Reduction Of Bleeding Episodes in Haemophilia A
Details : NNC0365-3769 (Mim8) is a next-gen FVIIIa mimetic antibody for sustained haemostasis, offering weekly or monthly prophylaxis for haemophilia A patients, with or without inhibitors.
Product Name : NNC0365-3769
Product Type : Antibody
Upfront Cash : Inapplicable
May 13, 2024
Lead Product(s) : Mim8
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dasiglucagon
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Declines to Approve Zealand Pharma's Drug for Low Blood Sugar in Infants
Details : ZP4207 (dasiglucagon) is a glucagon receptor agonist, peptide drug candidate, which is currently being evaluated for the treatment of congenital hyperinsulinism.
Product Name : Zegalogue
Product Type : Hormone
Upfront Cash : Inapplicable
December 21, 2023
Lead Product(s) : Dasiglucagon
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dasiglucagon
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZP4207 (dasiglucagon) is being investigated by Zealand Pharma for subcutaneous continuous infusion using a wearable pump system as a potential treatment of congenital hyperinsulinism in pediatric patients 7 days of age and older.
Product Name : Zegalogue
Product Type : Hormone
Upfront Cash : Inapplicable
August 30, 2023
Lead Product(s) : Dasiglucagon
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dasiglucagon
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Danske Bank
Deal Size : $218.9 million
Deal Type : Private Placement
Details : The net proceeds will be used for supporting the late stage rare disease assets, including Zegalogue (dasiglucagon), a glucagon analog that acts to increase blood sugar levels, being developed for the treatment of congenital hyperinsulinism.
Product Name : Zegalogue
Product Type : Hormone
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Dasiglucagon
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Danske Bank
Deal Size : $218.9 million
Deal Type : Private Placement
Lead Product(s) : Mim8
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mim8 Phase 1 & 2 Data Demonstrates Potential as Once Monthly Treatment for People With Haemophilia A
Details : Mim8 is a next-generation human IgG4 bispecific antibody bridging Factor IXa/X (FIXa/FX) designed to be a potent once weekly or once monthly prophylaxis therapy for people living with haemophilia A.
Product Name : NNC0365-3769
Product Type : Antibody
Upfront Cash : Inapplicable
November 07, 2022
Lead Product(s) : Mim8
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Concizumab
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Concizumab is an anti-TFPI mAB, designed to block a protein in body that stops blood from clotting, called TFPI. By blocking TFPI, concizumab encourages the production of a blood clotting protein called thrombin, which helps to clot the blood and prevent...
Product Name : Alhemo
Product Type : Antibody
Upfront Cash : Inapplicable
October 07, 2022
Lead Product(s) : Concizumab
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dasiglucagon
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dasiglucagon (ZP4207) is a glucagon analog that is stable in aqueous solution and is thus suitable for administration via chronic subcutaneous infusion via pump.Phase 3 study demonstrates that dasiglucagon treatment resulted in a significant reduction in...
Product Name : Zegalogue
Product Type : Hormone
Upfront Cash : Inapplicable
September 19, 2022
Lead Product(s) : Dasiglucagon
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable